A multicenter RCT evaluating a new oral anticoagulant versus warfarin in atrial fibrillation patients is ongoing in India. At the interim analysis (50% of planned enrollment, N = 800), the Data Safety Monitoring Board (DSMB) observes a significantly higher rate of major bleeding in the new drug arm (5.2% vs. 2.1%, p = 0.008) with no difference in stroke prevention. The DSMB must now make a recommendation. What is the most appropriate next step?